Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock

Making a noteworthy insider sell on December 16, Molly Harper, Director at Catalyst Pharmaceuticals (NASDAQ:CPRX), is reported in the latest SEC filing. What Happened: Harper's recent Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday unveiled the sale of 26,746 shares of Catalyst Pharmaceuticals. The total transaction value is $621,920. The latest market snapshot at Wednesday morning reveals Catalyst Pharmaceuticals shares down by 0.45%, trading at $24.08. Get to Know Catalyst Pharmaceuticals Better Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). A Deep Dive into Catalyst Pharmaceuticals's Financials Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 15.31% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector. Interpreting Earnings Metrics: Gross Margin: The company maintains a high gross margin of 84.73%, indicating strong cost management and profitability compared to its peers. Earnings per Share (EPS): With an EPS below industry norms, Catalyst Pharmaceuticals exhibits below-average bottom-line performance with a current EPS of 0.43. Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0. Financial Valuation Breakdown: Price to Earnings (P/E) Ratio: Catalyst Pharmaceuticals's P/E ratio of 14.15 is below the industry average, suggesting the stock may be undervalued. Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 5.31 suggests overvaluation in the eyes of investors, considering sales performance. EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Catalyst Pharmaceuticals's EV/EBITDA ratio at 7.71 suggests potential undervaluation, falling below industry averages. Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria. Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction. Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise. Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors. Unlocking the Meaning of Transaction Codes Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades. Insider Buying Alert: Profit from C-Suite Moves Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access. This article was generated by Benzinga's automated content engine and reviewed by an editor.